# Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)

> **NCT04140227** · PHASE3 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 256 (actual)

## Conditions studied

- Dry Eye Disease (DED)

## Interventions

- **DRUG:** NOV03

## Key facts

- **NCT ID:** NCT04140227
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-24
- **Primary completion:** 2022-01-05
- **Final completion:** 2022-01-05
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2024-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04140227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04140227, "Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04140227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*